Raphael Reinbold

Senior Scientist in Biochemistry & Structural Biology at OMass Therapeutics, Chemical Biology PhD University of Oxford, Pharmacist

[FierceBiotech @FierceBiotech]

Roche’s Genentech unit is offering up to $420 million for Omass Therapeutics’ preclinical inflammatory bowel disease program.
https://t.co/Ts4gLnz4dB

[OMass Therapeutics @omasstx]

Our Principal Scientist, Christine Oswald & Senior Scientist, Raphael Reinbold will be attending the 9th @RSC_BMCS / @SCIupdate Symposium on GPCRs in Medicinal Chemistry taking place from 2nd – 4th October in Verona, Italy.

Get in touch to find out more about our #GPCR programs.

[Kawamura Group @KawamuraGroup]

Very exciting to see @KlemSimelis’ #phdresearch on targeting TET #enzymes using #cyclicpeptide inhibitors in #Bioorganic & #MedicinalChemistry!

A great collaboration with the Suga group & @SchofieldOxford.

Read Klem's paper online: https://t.co/ng3UOvjQv2

#chemicalbiology

[Adam Matthew Thomas @AdamMThomasChem]

Hot off the press! Check out our ‘mutate and conjugate’ paper in @ACSBioMed 🔥
Here we demonstrate that combining site-directed mutagenesis and reactive fragments can be used to rapidly identify selective covalent probes for target validation studies.

[Stuart Conway @conway_group]

Our latest manuscript ‘Mutate and Conjugate: A Method to Enable Rapid In-Cell Target Validation’ is now available on @ChemRxiv Nice work from all authors including: @AdamMThomasChem @MartaSerafini3 @emma_k_grant @Joe_P_B @MatthiasSchied2 https://t.co/of9AtqWwDT #chembio #chembiol

[Adam Matthew Thomas @AdamMThomasChem]

My DPhil project has just landed on ChemRxiv! Thanks to all the collaborators🧪🧫

[Raphael Reinbold @RaphaelRe1]

I am excited about starting a new position as senior scientist at OMass Therapeutics!

[OMass Therapeutics @omasstx]

A big welcome to Raphael Reinbold who joins our Oxford team as Senior Scientist.

Our team continues to expand as we enter an exciting stage of development.
To learn more about OMass, visit our website: https://t.co/eB63lkzrth
#drugdiscovery #proteinbiochemistry #newjoiner

[Raphael Reinbold @RaphaelRe1]

As always great to meet for Schnitzel! I also want to add that we indeed finished all of it 😉

[Manfred Jung @ChemEpi]

Great to have @RaphaelRe1 visit again from Oxford. As always with Jörg and Maxi. It had to be the Elephant ear at Eble (right Panel) of course.

[Raphael Reinbold @RaphaelRe1]

@LuizCarvalhoLAB @KawamuraGroup @SchofieldOxford Congrats, Steph!! :)

[Raphael Reinbold @RaphaelRe1]

@KawamuraGroup @Grace__Roper @GroupBrennan @aisidrollobet @TheCrick @GSK @ChemBioCDT_Ox @OxfordChemistry @EPSRC Huge congrats @Grace__Roper !! 😊

[Ryan Herold @RyanAHerold]

I'm thrilled to share my latest paper which is now out in PNAS! We report a NADP(H)-dependent enzyme system that runs without any added NADP(H) when entrapped in a nanoporous electrode.
@OxfordChemistry @TrinityOxford @PNASNews @Clarendon_OU https://t.co/KR7kKaH9Ct

[Raphael Reinbold @RaphaelRe1]

Always great to visit home and to catch up over huge portions of Schnitzel 🤩

[Manfred Jung @ChemEpi]

@RaphaelRe1 visting home from Oxford. Together with alumnus Jörg and PhD Student Maxi (also alumnus of @SchofieldOxford ) at the local Schnitzel palace Eble in Sexau

[Manfred Jung @ChemEpi]

@RaphaelRe1 visting home from Oxford. Together with alumnus Jörg and PhD Student Maxi (also alumnus of @SchofieldOxford ) at the local Schnitzel palace Eble in Sexau

[Diamond MX Beamlines @Diamond_MX]

New Paper from @beamlineI24 in @NatureComms https://t.co/7MGHlSgVi5 (https://t.co/FI3ZdOqmMf)

[Nature Communications @NatureComms]

Researchers at @OxfordChemistry, @RaphaelRe1 and @SchofieldOxford, report studies on resistance to the pioneer drug ivosidenib leading to identification of inhibitors retaining activity.

https://t.co/AgOsr1509x

[University of Oxford @UniofOxford]

Researchers from @OxfordChemistry have published a study investigating the mechanism behind a resistance to the drug ivosidenib that has developed in some types of cancer.

More info ⬇️
https://t.co/mHV91mC0My

[Oxford Chemistry @OxfordChemistry]

Hot off the press 🦠 Drug-resistant cancer mutations, and how we might be able to overcome them:

[Schofield Group @SchofieldOxford]

You can read about our latest story on overcoming drug-resistant cancer mutations with novel inhibitors on @OxfordChemistry website: https://t.co/dOSSqgi5mD #sciencecommunication

[Raphael Reinbold @RaphaelRe1]

Check out this thread about our new publication!

[Dr Martine I. Abboud @MartineAbboud]

New publication explained. A thread 👇 https://t.co/Odn4lKqQDU

[Raphael Reinbold @RaphaelRe1]

@ChemEpi @NatureComms @SchofieldOxford @OxfordChemistry @UniFreiburg @4500MilesOxford Thank you so much for the kind words, Manfred! :) Yes definetly, looking forward to go to @4500MilesOxford again

[Raphael Reinbold @RaphaelRe1]

Finally, our story about overcoming IDH1 drug resistance is out in @NatureComms. While ivosidenib loses actvity, two other inhibitors (FT-2102, DS-1001B; both in phase 2 trials) retain activity in a cellular environment https://t.co/5AxpdR6IIu
@SchofieldOxford
@OxfordChemistry